Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Sarcoma 1Endocrine 1

Conditions

Paraganglioma 1

Interventions

lutetium Lu 177 dotatate 30Magnetic Resonance Spectroscopy 25pembrolizumab 21Specimen Handling 18Nivolumab 17cabozantinib 14lenvatinib 12Everolimus 12trametinib 11gallium Ga 68 dotatate 10dabrafenib 10Ipilimumab 10Carboplatin 10Cisplatin 8atezolizumab 7Temozolomide 7Lutetium-177 7X-Rays 6Etoposide 6Capecitabine 6surufatinib 5lanreotide 5fluorodopa F 18 5cemiplimab 5Vemurafenib 5Paclitaxel 5Octreotide 5Lutetium 5Fluorodeoxyglucose F18 5Disulfides 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ONC206 × Endocrine × 1 year × Clear all
NCT07282587 2026-02-27

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

Jazz Pharmaceuticals

Phase 2 Recruiting
90 enrolled
CNSEndocrine

Paraganglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡